Latest Ndis News

Freedom Care Group Holdings has placed its main operating entity into administration following a sharp decline in cash receipts linked to delayed payments from the NDIA and an ongoing audit. The company’s cash balance dropped significantly, prompting urgent restructuring efforts.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

Bridge SaaS Limited reported a robust September quarter, buoyed by its majority-owned Brightside subsidiary's profitability and participant growth, while preparing to launch new NDIS services in New South Wales.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

McMillan Shakespeare Limited reported steady FY25 growth with Normalised UNPATA of $103.2 million and an 8.3% dividend yield, underpinned by digital innovation and strategic investments.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

PeopleIN Limited posted a statutory net loss of $11.862 million for FY25, impacted by tough economic conditions and weather disruptions, while achieving significant cost savings and announcing a $6 million share buy-back.

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

Bridge SaaS Limited reports steady cash flow and strategic focus on AI and robotics to transform disability care under the NDIS framework.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.